Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A. Hulton, John C. Lieske, Wesley Hayes et al.|Kidney International Reports|2021Cited by 32
Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective StudyJohn C. Lieske, John M. Gansner, Jaap W. Groothoff et al.|Kidney Medicine|2025Cited by 2
MP07-09 12-MONTH ANALYSIS OF ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN: SUSTAINED OXALATE LOWERING AND KIDNEY STONE EVENT RATES IN PRIMARY HYPEROXALURIA TYPE 1Dean G. Assimos, John C. Lieske, Jeffrey M. Saland et al.|The Journal of Urology|2021Cited by 0
Analyse à 12 mois d’ILLUMINATE-A, une étude de phase 3 du lumasiran : réduction durable de l’oxalate et des taux d’évènements de calculs rénaux dans l’hyperoxalurie primitive de type 1Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff et al.|Néphrologie & Thérapeutique|2021Cited by 0